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Background: The fibroblast growth factors (FGF) 19 subfamily, also referred to as
endocrine FGFs, includes FGF19, FGF21, and FGF23 are metabolic hormones involved
in the regulation of glucose and lipid metabolism. Fetuin-A is a hepatokine involved in the
regulation of beta-cell function and insulin resistance. Endocrine FGFs and fetuin-A are
dysregulated in metabolic disorders including obesity, type 2 diabetes, non-alcoholic fatty
liver disease and polycystic ovary syndrome (PCOS). Our study was designed to examine
the response of endocrine FGFs and fetuin-A to an acute intralipid, insulin infusion and
exercise in PCOS and healthy women.
Subjects and Measurements: Ten healthy and 11 PCOS subjects underwent 5-h
saline infusions with a hyperinsulinemic-euglycemic clamp (HIEC) performed during the
final 2 h. One week later, intralipid infusions were undertaken with a HIEC performed
during the final 2 h. After an 8 week of exercise intervention the saline, intralipid, and
HIEC were repeated. Plasma levels of endocrine FGFs and fetuin-A were measured.
Results: Baseline fetuin-A was higher in PCOS women but FGF19, FGF21, and FGF23
did not differ and were unaffected by exercise. Insulin administration elevated FGF21
in control and PCOS, suppressed FGF19 in controls, and had no effects on FGF23 and
fetuin-A. Intralipid infusion suppressed FGF19 and increased FGF21. Insulin with intralipid
synergistically increased FGF21 and did not have effects on lipid-mediated suppression
of FGF19 in both groups.
Conclusion: Our study provides evidence for insulin and lipid regulation of endocrine
FGFs in healthy and PCOS women, suggesting that FGF family members play a role in
lipid and glucose metabolism.
Clinical Trial Registration: www.isrctn.org, Identifier: ISRCTN42448814.
Keywords: PCOS (polycystic ovarian syndrome), FGF (fibroblast growth factor), Fetuin A, hyperinsulimic-
euglycemic clamp, FGF19, FGF21
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INTRODUCTION
PCOS is a hormonal and metabolic disorder that affects about
ten percent of women in the reproductive age group. Women
with PCOS are more susceptible to insulin resistance (IR),
myocardial infarction, fertility problems, type 2 diabetes (T2D),
and cardiovascular disorders. The fibroblast growth factor (FGF)
family has 22 members that are divided into further 7 subgroups
based on phylogenetic similarity. FGFs function by binding
to 4 tyrosine kinase receptors called FGF receptors (FGFRs)
(1). FGF19 subfamily, also referred to as endocrine FGFs,
includes FGF19, FGF21, and FGF23 that circulate in the blood
and act on multiple organs involved in the regulation of
metabolism. Endocrine FGFs have lower affinity for FGFRs and
form complexes with Klotho proteins to elicit their biological
functions in target tissues. Small intestinal cells are the main
source of circulating FGF19; and in rodents FGF19 reduces
hepatic triglycerides and glucose levels, promotes fatty acid
oxidation by inhibiting acetyl CoA carboxylase 2, and enhances
insulin sensitivity (2). FGF19 expression is regulated by farnesoid
X receptor; and bile acids increase the circulating levels of
FGF19 (3).
FGF21 is expressed in liver, thymus, adipose tissues, pancreas,
skeletal muscle, kidney, and heart (4). Administration of FGF21
reduces bodyweight in obese mice (5, 6) and promotes insulin
sensitivity in diabetic mouse models, with reductions in plasma
glucose, triglycerides, glucagon, and insulin levels (4). FGF23,
which is mainly produced by osteocytes, is involved in the
regulation of phosphate levels and vitamin D synthesis in the
kidney (7). High plasma levels of FGF23 are associated with
end-stage renal disease, cardiovascular diseases, and death (8, 9).
Fetuin-A is a circulating glycoprotein synthesized mainly in the
liver and is involved in the regulation of insulin signaling. In
adipocytes, fetuin-A increases the accumulation of triacylglycerol
and fatty acid uptake and enhances lipogenesis (10). Circulating
fetuin-A levels are higher in obesity, T2D and non-alcoholic
fatty liver disease (NAFLD) and is associated with impaired
insulin sensitivity (11). Studies have shown that fetuin-A directly
interacts with the insulin receptor and alters insulin signaling
by disrupting insulin-stimulated phosphorylation of the insulin
receptor and insulin receptor substrate-1 (12).
Previous studies have shown differences in circulating levels
of endocrine FGFs (13, 14) and fetuin-A (15) in PCOS women.
FsGF21 and fetuin-Awere reported to be elevated and FGF19was
found to be lower in PCOS women compared to healthy controls
(13–15). Acute intralipid administration elevates circulating free
fatty acid (FFA) and triglycerides, decreases peripheral glucose
Abbreviations: PCOS, Polycystic ovary syndrome; T2D, Type 2 diabetes; IR,
insulin resistance; IS, Insulin sensitivity; Endocrine FGF, FGF19, FGF21, and
FGF23; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; TCH, total cholesterol; HDL, high density lipoprotein; LDL, low
density lipoprotein; TG, triglycerides; HbA1c, glycated hemoglobin; ALT, alanine
aminotransferase; HIEC, hyperinsulinemic-euglycemic clamp; FGF, fibroblast
growth factor; NAFLD, non-alcoholic fatty liver disease; HOMA-IR, homeostatic
model assessment of insulin resistance; NEFA, non-esterified fatty acids; FSH,
follicle-stimulating hormone; SHGB, sex hormone binding globulin; FAI, free
androgen index.
uptake resulting in increased insulin resistance (16–18). Regular
exercise improves insulin signaling in skeletal muscle, promotes
insulin sensitivity, improves cardio-metabolic fitness, and overall
health (19). The role of endocrine FGFs and fetuin-A in intralipid
mediated insulin resistance or in enhanced insulin sensitive states
induced by exercise is not fully understood. Therefore, the aim of
this study was to understand the relationship between endocrine
FGFs and fetuin-A response to IR induced by intralipids and the
combination of intralipids and insulin in women with PCOS and
healthy control women.
STUDY DESIGN AND METHODOLOGY
Ethical Approval
The study was approved by the Yorkshire and the Humber
Research Ethics Committee (reference number 10/H1313/44)
and The Medical Research Center at Hamad Medical
Corporation (reference number RP #17180/17) all study
participants gave their written informed consent before
participation. Intralipid and euglycemic clamp studies were
conducted in the clinical research facility at Hull and East
Yorkshire Hospital.
Study Subjects and Insulin/Intralipid Clamp
Protocol
The study subjects were matched for age, weight and BMI, non-
smokers, were not on any medication and had no concurrent
illness. PCOS was diagnosed according to the Rotterdam criteria
(20). Eleven PCOS and 10 healthy volunteers were recruited
as reported previously (21, 22). Following the collection of
overnight fasted blood samples all the subjects underwent a
5-h saline infusion with insulin sensitivity (IS) assessed by a
hyperinsulinemic-euglycemic clamp (HIEC) in the final 2 h to
determine the glucose disposal rate (M value). A week later, all
participants underwent 5 h intralipid infusion (20% soybean oil,
1.2% egg yolk phospholipids, and 2.2% glycerol; Kabi Fresenius
Pharmacia) with a HIEC in the last 2 h to determine theM-value
(21). HIEC was started using intravenous soluble insulin at a
rate of 80 mU/m2 surface area/min for the first 20min, followed
by a constant rate of 40 mU/m2 surface area/minute for the
remaining 100min. Plasma glucose was clamped at 5.0 mmol/L
with a variable infusion rate of 20% dextrose, adjusted relative
to arterialized blood glucose measurements undertaken every
5min. Blood samples were collected at 0, 180, 240, and 300min
for measurement of various proteins. On completion of the
procedure all the participants underwent supervised moderate
intensity (60% maximum oxygen consumption) exercise, 3 h
weekly for 8 weeks. Healthy control women had the initial
clamp in the first week of their menstrual cycle, whilst PCOS
women were clamped after 6 weeks amenorrhea as reported
previously (21).
Exercise Intervention
All the participants underwent a 1-h supervised walking exercise
program three times per week for a total of 8 weeks in the
department of Sports, Health and Exercise Science, University
of Hull. VO2 max was measured in a motorized treadmill
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with warm-up followed by speeding to walking pace and
increasing the walking pace every minute until the study
participants could not keep pace with the treadmill or become
too tired to continue. Exercise sessions achieved heart rate
equivalent to 60% of baseline VO2 max. The heart rate and
inspired/expired gas fractions were monitored continuously
using the same instrument used in the training program for each
patient (16, 23). After the exercise intervention, anthropometric
measurements, blood biochemistry, saline, lipid infusions, and
HIEC were repeated in these subjects as reported previously
(22). Repeat saline studies for each individual were performed
immediately after the 3-month interventional exercise phase and
the lipid studies performed 1 week later as for the initial saline
lipid sequence.
Biochemical Measurements
Plasma levels of FGF19 were measured using quantitative
sandwich ELISA kit (R&D Systems, MN, USA; Catalog#
DF1900). The kit had a mean minimum detectable dose (MDD)
of 1.17 pg/ml, quantification range of 15.6–1,000 pg/ml, intra-
assay coefficient of variation (CV) <6.4% and inter-assay
CV <5.5%. Fetuin A concentrations in serum samples were
quantified using a commercially available Quantikine ELISA
kit (R&D Systems, MN, USA; Catalog# DFTA00). The kit
has a mean MDD of 0.62 ng/ml, quantification range of 7.8–
500 ng/ml, inter-assay CV <7.4% and intra-assay CV <8.4%.
Serum concentrations of FGF21 and FGF23 were measured
using Milliplex MAP kit -Human Liver Protein Magnetic Bead
Panel (EMD Millipore, MA, USA, Catalog # HLPPMAG-
57K). The kit had a detection range of 0.01–10 ng/mL for
FGF21(inter-assay CV <12% and intra-assay CV <2%) and
0.04–30 ng/mL for FGF23 (inter-assay CV <15% and intra-assay
CV<3%). Belowmentioned variables were measured as reported
previously (21) serum insulin was measured using a competitive
chemiluminescent immunoassay (Euro/DPC, Llanberis, UK).
Plasma glucose was measured by Synchon LX 20 analyzer
(Bechman-Coulter, High Wycombe, UK). Triglycerides (TG)
and total cholesterol measurements were done using a Synchon
LX 20 analyzer (Beckman-Coulter). The free androgen index
(FAI) was calculated by dividing the total testosterone by SHBG,
and then multiplying by 100. Serum testosterone (nmol/L) was
assessed by high-performance liquid chromatography linked to
tandem mass spectrometry (Waters Corporation, Manchester,
UK), sex hormone binding globulin (SHBG) (nmol/L) levels were
measured by immunometric assay with fluorescence detection
on the DPC Immulite 2,000 analyzer (Euro/DPC, Llanberis UK).
FSH (iu/L) was measured by an Architect analyzer (Abbott
Laboratories, Maidenhead, UK); TCH (mmol/L), TG (mmol/L),
and HDL (mmol/L) were measured using a Synchron LX
20 analyzer (Beckman-Coulter); LDL (mmol/L) was calculated
using the Friedewald equation. Plasma glucose was measured
using a Synchron LX 20 analyzer (Beckman-Coulter). NEFA
was measured using an enzymatic colorimetric method (Wako
NEFA-H2) on a Konelab20 auto analyzer with a coefficient of
variation of 1.4%. All the above measurements were performed
according to manufacturer’s recommended protocol.
Statistical Analysis
All measurements are expressed as means ± standard deviation
(SD). The differences in baseline demographic, clinical, and
biochemical data between PCOS vs. control were assessed by
unpaired t-test. Comparisons of FGF19, FGF21, FGF23, and
fetuin-A in the control and PCOS groups before and after the
exercise intervention were determined by two-way ANOVA.
For saline, intralipid, and insulin infusion experiments repeated
measure one-way ANOVA analysis was performed to determine
significant differences between all the timepoints within control
group and PCOS separately. A post hoc analysis (Bonferroni)
correction was performed to evaluate significant differences
between each time point to its respective baseline measurements
for control and PCOS groups that were done separately.
Comparison between control and PCOS groups during saline-
insulin infusion and lipid-insulin infusion studies were done
by two-way RM ANOVA analysis. Pearson Rank correlation
was used to evaluate significant associations between FGF19,
FGF21, FGF23, and fetuin-A with clinical variables. Statistical
significance was set at p <0.05. The statistical package SPSS 22.0
and Graphpad prism 5 software was used for the data analysis
and graphical representation of results.
RESULTS
Characteristics of the Study Subjects
Demographics, clinical variables, and biochemical measurements
of the study participants were reported previously (21). In
brief, women with PCOS had increased body weight, higher
insulin resistance, and elevated liver enzymes but decreased
sex hormone binding globulin (Supplementary Table 1).
At baseline, plasma concentrations of fetuin-A were
elevated in PCOS (P < 0.05) but FGF19, FGF21, FGF23
levels were similar in the PCOS and control groups
(Figure 1). Following exercise there was a reduction in
waist circumference (p = 0.05), but no significant changes
in weight (p = 0.40) (21). Unpaired t-test was performed to
determine significant differences between control and PCOS
baseline measurements.
Effects of Acute Insulin Infusion on
Circulating Lipids, Endocrine FGFs, and
Fetuin-A
As reported previously (21), insulin sensitivity index (M-value)
was lower in PCOS (P < 0.05); and insulin infusion suppressed
plasma concentrations of TG (P < 0.0001) and non-esterified
fatty acids (NEFA) (P < 0.0001). Two-way RM ANOVA analysis
comparing between control and PCOS group showed no changes
for FGF19, FGF21, FGF23, and Fetuin-A between the groups.
One-way ANOVA analysis comparing differences for each of
FGF19, 21, 23, and fetuin-A at the 3 time points of baseline,
180 and 300min within the control group or within the PCOS
groups showed that insulin infusion significantly increased the
plasma concentrations of FGF21 (P < 0.05) in both PCOS
and control women by 77 and 63%, respectively (P < 0.01);
decreased FGF19 was seen only in the control group as assessed
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FIGURE 1 | Baseline expression of metabolic hormones (A) FGF19, (B) FGF21, (C) FGF23, and (D) fetuin-A in control (n = 10) and PCOS (n = 11) women. The
un-paired t-test was performed to compare differences between control and PCOS group. A *p < 0.05 of was considered significant. FGF19, fibroblast growth factor
19; FGF21, fibroblast growth factor 21; FGF23, fibroblast growth factor 23.
TABLE 1 | Effects of acute insulin administration on circulating lipids, endocrine FGFs, and fetuin-A in control (n = 10) and PCOS (n = 11) subjects.
Control One-way post-hoc PCOS One-way post-hoc Two-way
(N = 10) ANOVA analysis (N = 11) ANOVA analysis RM ANOVA
Infusion (min) Mean ± SD p p Mean ± SD p p p
FGF19 (pg/ml) Baseline (0) 109.30 ± 52.2 * 83.32 ± 50.8 NS NS
Saline (180) 85.37 ± 32.2 61.59 ± 39.6
Saline + Ins (300) 63.39 ± 30.9 # 66.37 ± 50.5
FGF21 (pg/ml) Baseline (0) 120.00 ± 87.7 * 167.00 ± 89.2 ** NS
Saline (180) 121.50 ± 91.7 128.50 ± 58.1
Saline + Ins (300) 215.00 ± 55.5 # 208.00 ± 103.7 ##
FGF23 (pg/ml) Baseline (0) 120.00 ± 43.5 NS 125.6 ± 45.0 NS NS
Saline (180) 88.33 ± 41.7 96.67 ± 23.5
Saline + Ins (300) 86.67 ± 29.4 103.30 ± 24.5
Fetuin-A (µg/ml) Baseline (0) 0.72 ± 0.2 NS 0.82 ± 0.2 NS NS
Saline (180) 0.72 ± 0.1 0.80 ± 0.2
Saline + Ins (300) 0.70 ± 0.2 0.78 ± 0.1
M-value 5.0 ± 2.0 3.3 ± 0.8
One-way ANOVA group analysis was performed in controls to determine significant differences for FGF19, 21, 23 and fetuin-A between time points within control group *p < 0.05.
post hoc analysis with Bonferroni correction was performed for subgroup analysis to compare each time point measurements within control group to control baseline expression ##p
< 0.001; #p < 0.05. This one-way ANOVA group analysis was repeated in PCOS women separately **p < 0.001, and post hoc analysis was also repeated comparing each time point
measurements within PCOS group to baseline expression levels in the PCOS group ##p < 0.001. Two-way RM ANOVA analysis was performed to compare between control and PCOS
group. FGF19, fibroblast growth factor 19; FGF21, fibroblast growth factor 21; FGF23, fibroblast growth factor 23; M-value, Insulin sensitivity index; NS, non-significant.
by one-way ANOVA comparing all the timepoints within control
group, and there were no effects on plasma levels of FGF23 or
fetuin-A in either groups (Table 1). Further post hoc analysis
showed compared to baseline (0min), insulin infusion at 300min
reduced FGF19 in controls. In contrast, insulin increased FGF21
secretion at 300min both in control and PCOS compared
to their respective baseline (0min) measurements in the post
hoc analysis.
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TABLE 2 | Effects of acute intralipid and combination of intralipid plus insulin administration on circulating lipids, endocrine FGFs, and fetuin- in control (n = 10) and PCOS
(n = 11) subjects.
Control One-way post-hoc PCOS One-way post-hoc Two-way
(N = 10) ANOVA analysis (N = 11) ANOVA analysis RM ANOVA
Infusion (min) Mean ± SD p p Mean ± SD p p p
FGF19 (pg/ml) Baseline (0) 129.5 ± 94.3 ** 84.67 ± 58.4 *** NS
Lipid (60) 65.08 ± 36.0 # 33.4 ± 15.8 ###
Lipid (180) 53.1 ± 37.3 ## 35.73 ± 18.9 ###
Lipid + Ins (240) 44.07 ± 24.7 ## 41.15 ± 19.8 ##
Lipid + Ins (300) 57.10 ± 19.5 # 45.79 ± 19.9 ##
FGF21 (pg/ml) Baseline (0) 163.00 ± 102.0 *** 143.60 ± 124.6 *** $
Lipid (60) 114.50 ± 91.2 138.20 ± 174.6
Lipid (180) 231.00 ± 164.8 ### 309.10 ± 174.8 ###
Lipid + Ins (240) 403.00 ± 275.7 ### 600.90 ± 339.6 ###
Lipid + Ins (300) 959.00 ± 618.3 ### 1056.00 ± 386.5 ###
FGF23 (pg/ml) Baseline (0) 139.00 ± 45.3 ** 138.20 ± 62.9 NS NS
Lipid (60) 105.00 ± 47.2 136.40 ± 62.49
Lipid (180) 103.00 ± 55.8 123.60 ± 58.01
Lipid + Ins (240) 85.00 ± 26.7 ## 120.00 ± 59.8
Lipid + Ins (300) 116.00 ± 57.4 159.10 ±109.2
Fetuin-A (µg/ml) Baseline (0) 0.68 ± 0.2 NS 0.82 ± 0.2 NS NS
Lipid (60) 0.74 ± 0.2 0.84 ± 0.2
Lipid (180) 0.71 ± 0.1 0.78 ± 0.2
Lipid + Ins (240) 0.68 ± 0.1 0.80 ± 0.2
Lipid + Ins (300) 0.72 ± 0.1 0.81 ± 0.2
M-value 2.4 ± 1.7 1.2 ± 0.8
One-way ANOVA group analysis was performed in controls to determine significant differences between time points for FGF19, 21, 23 and fetuin-A within control group ***p < 0.0001;
**p < 0.001. post hoc analysis with Bonferroni correction for subgroup analysis comparing each the time point with control baseline expression ###p < 0.0001; ##p < 0.001; #p <
0.05. Similarly, One-way ANOVA group analysis was performed in PCOS women separately ***p < 0.0001; **p < 0.001, with the post hoc analysis undertaken to compare each time
point measurements within the PCOS group to baseline expression levels in the PCOS group ###p < 0.0001; ##p < 0.001. Two-way RM ANOVA analysis was performed to compare
between control and PCOS group; $p < 0.05. FGF19, fibroblast growth factor 19; FGF21, fibroblast growth factor 21; FGF23, fibroblast growth factor 23; M-value, Insulin sensitivity
index; NS, non-significant.
Effects of Intralipid and Combination of
Intralipid and Insulin Infusions on
Circulating Endocrine FGFs and Fetuin-A
As reported previously, intralipid infusion dramatically increased
plasma TG, and NEFA concentrations in control and PCOS
women; and had no effects on cholesterol levels (15). Two-way
RM ANOVA analysis comparing between control and PCOS
showed a significant increase in FGF21 (P < 0.05) between
the groups and no changes were observed for FGF19, FGF23,
and Fetuin-A. However, one-way ANOVA analysis assessing
changes within the control or the PCOS groups during the time
course showed that intralipid and a combination of intralipid
and insulin suppressed FGF19 in control (P < 0.01) and in the
PCOS groups (P < 0.0001). Further post hoc analysis showed
that the intralipid infusion suppressed the plasma concentration
of FGF19 in both control (P < 0.01) and PCOS (P < 0.0001)
to 50 and 39% of baseline at 60min, respectively; and the
levels remained suppressed during insulin infusion at 300min
(Table 2). In contrast, one-way ANOVA showed both intralipid
and combination of intralipid and insulin increased FGF21 both
in control (P < 0.0001) and PCOS group (P < 0.0001) over
the time course. Further post hoc analysis showed that intralipid
infusion in control subjects had a biphasic effect on FGF21;
decreased FGF21 concentrations to 70% of baseline at 60min but
increased its concentrations to 141% of baseline at 180min (P
< 0.05, Table 2). A similar pattern was also observed in PCOS
women (P < 0.01, Table 2). Insulin infusion, added to intralipid
during the last 2 h, further increased plasma FGF21 to 247% and
585% of baseline at 240 and 300min, respectively, in control
subjects (P< 0.0001,Table 2, post-hoc analysis). A similar pattern
was also observed in PCOS women (P < 0.0001, post-hoc analysis
Table 2). Intralipid infusion alone had no effect on FGF23 or
fetuin-A in both groups (Table 2); the addition of insulin along
with intralipid decreased FGF23 only in the control group (P <
0.01). And did not change the plasma levels of FGF19 or fetuin-A
during the euglycemic clamp in PCOS women (Table 2).
Moderate Exercise Training Does Not Alter
Circulating Endocrine FGFs and Fetuin-A
As reported previously, exercise improved insulin sensitivity
and overall fitness in both control and PCOS women with an
improvement of VO2 max. However, there were no significant
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FIGURE 2 | Effect of exercise on expression of metabolic hormones (A) FGF19, (B) FGF21, (C) FGF23, and (D) fetuin-A in control (n = 10) and PCOS (n = 10)
women. BE, before exercise; AE, after exercise. Statistical differences in metabolic hormones expression following exercise in control and PCOS were measured by
two-way ANOVA. FGF19, fibroblast growth factor 19; FGF21, fibroblast growth factor 21; FGF23, fibroblast growth factor 23; NS, non-significant.
changes in the plasma levels of metabolic hormones FGF19,
FGF21, FGF23, and fetuin-A in either group before or after
exercise (Figure 2). Comparison of FGF19, FGF21, FGF23, and
fetuin-A in the control and PCOS group before and after the
exercise intervention was determined by two-way ANOVA.
Correlation Analysis of FGF19, FGF21,
FGF23, and Fetuin-A With Covariates
In all the participants, Pearson Rank analysis was performed
to study the association of endocrine FGFs and fetuin-A with
baseline clinical and biochemical parameters (Table 3). Our
analysis showed that plasma FGF19 levels significantly correlated
negatively with hip circumference (r = −0.433, P < 0.05). FGF-
21 correlated positively with plasma FGF-23 (r = 0.456, P <
0.05) and diastolic blood pressure (r = 0.487, P < 0.05). FGF-23
showed negative association with total cholesterol concentration
(r = −0.478, P < 0.05). Similarly, fetuin-A correlated positively
with weight (r = 0.473, P < 0.05), BMI (r = 0.521, P < 0.05), hip
circumference (r= 0.454, P < 0.05), plasma glucose (r= 0.478, P
< 0.05), and insulin (r = 0.571, P < 0.01) levels, and HOMA-IR
(r = 0.616, P < 0.01).
DISCUSSION
Endocrine FGFs and fetuin-A regulate a broad spectrum of
metabolic functions such as glucose, lipid metabolism, and
energy homeostasis by regulating several signaling cascades that
lead to altered insulin sensitivity (11, 24). We hypothesized that
disrupting glucose and lipid homeostasis by acute intralipid and
insulin administration or via moderate exercise may differentially
modulate circulating endocrine FGFs and fetuin-A in healthy
women and women with PCOS. Thus, to address this hypothesis,
we analyzed plasma levels of endocrine FGFs and fetuin-A before
and after a supervised exercise program. We further studied the
role of short-term hyperlipidemia mediated insulin resistance
induced by intravenous administration of intralipid via lipid
clamp and insulin administration via HIEC on plasma levels of
endocrine FGFs and fetuin-A. As reported previously, intralipid
infusion induced insulin resistance both in control and PCOS
subjects as shown by the lowering of insulin stimulated glucose
disposal rates during the intralipid clamp (16). Compared to
controls, the insulin stimulated glucose disposal rate showed
greater suppression in PCOS (16).
In our study, fetuin-A was found to be significantly higher
in PCOS compared to controls, but there were no significant
differences observed for FGF19, FGF21, and FGF23 between
the groups. Plasma fetuin-A levels positively associated with
risk factors for IR such as weight, BMI, plasma glucose,
insulin, and HOMA-IR. In concordance with our finding
in PCOS, fetuin-A levels were reported to be elevated in
insulin-resistant T2D subjects, positively correlated with insulin
resistancemarkers such as HOMA-IR, glycated hemoglobin, low-
density lipoprotein cholesterol, BMI, and negatively correlated
with fasting insulin, high-density lipoprotein cholesterol, and
HOMA-β-cell insulin secretion index (25), and fetuin-A was
shown to antagonize insulin action at cellular levels with direct
inhibition of insulin binding to its receptor (26, 27). Evidence
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TABLE 3 | Pearson Rank correlation of FGF19, FGF21, FGF23, and fetuin-A with anthropometric and blood biochemical variables.
FGF-19 FGF-21 FGF-23 Fetuin-A
Pearson correlation r p r p r p r p
FGF-19 1.000 0.079 0.741 0.301 0.185 −0.016 0.944
FGF-21 0.079 0.741 1.000 0.456* 0.043 −0.152 0.521
FGF-23 0.301 0.185 0.456* 0.043 1.000 −0.089 0.700
Fetuin-A −0.016 0.944 −0.152 0.521 −0.089 0.700 1.000
age −0.035 0.879 0.118 0.621 −0.196 0.395 0.319 0.159
Height −0.224 0.329 0.110 0.646 0.186 0.419 0.016 0.945
Weight −0.278 0.223 −0.188 0.427 0.128 0.581 0.473* 0.030
BMI −0.213 0.353 −0.227 0.336 0.065 0.780 0.521* 0.015
Waist −0.295 0.195 −0.144 0.543 0.031 0.893 0.430 0.052
Hip −0.433* 0.050 −0.103 0.665 −0.009 0.969 0.454* 0.039
WHR 0.128 0.580 −0.158 0.506 0.127 0.582 0.138 0.551
SBP −0.013 0.954 0.340 0.143 0.057 0.806 0.183 0.428
DBP −0.367 0.102 0.487* 0.030 0.272 0.233 0.383 0.087
PG 0.296 0.193 −0.158 0.505 −0.252 0.270 0.478* 0.028
Insulin 0.019 0.935 −0.178 0.453 0.249 0.277 0.571** 0.007
HOMA-IR 0.059 0.798 −0.185 0.436 0.171 0.460 0.616** 0.003
M-value 0.248 0.279 −0.158 0.505 −0.240 0.295 −0.303 0.182
NEFA −0.138 0.550 −0.056 0.813 −0.425 0.055 −0.257 0.261
TCH −0.291 0.200 0.009 0.971 −0.478* 0.028 −0.176 0.444
Testosterone 0.071 0.759 −0.250 0.288 0.536* 0.012 0.231 0.314
FAI −0.190 0.408 −0.410 0.072 0.222 0.334 0.375 0.094
SHBG 0.406 0.068 0.487* 0.030 0.008 0.971 −0.286 0.210
LH −0.248 0.292 0.182 0.456 0.264 0.261 0.029 0.902
FSH 0.157 0.509 0.036 0.883 −0.208 0.379 0.445* 0.049
Estradiol −0.297 0.203 −0.082 0.739 0.364 0.114 −0.081 0.735
TG −0.240 0.295 0.054 0.820 −0.220 0.338 0.010 0.967
HDL −0.193 0.403 −0.170 0.473 −0.487* 0.025 −0.296 0.192
LDL −0.164 0.478 0.212 0.370 0.275 0.228 0.024 0.919
ALT −0.190 0.423 −0.266 0.271 0.010 0.968 0.235 0.319
HbA1c −0.153 0.532 −0.047 0.854 −0.296 0.219 0.339 0.155
Prolactin 0.272 0.259 −0.309 0.212 0.122 0.620 −0.162 0.507
TSH −0.029 0.902 −0.015 0.949 0.163 0.479 −0.079 0.732
DHEAS 0.130 0.596 −0.184 0.466 0.311 0.194 −0.381 0.108
Androsterone −0.162 0.508 −0.346 0.159 0.235 0.332 −0.283 0.241
p is the two tailed significance and r is Pearson correlation coefficient. FGF19, fibroblast growth factor 19; FGF21, fibroblast growth factor 21; FGF23, fibroblast growth factor 23; BMI,
Body mass index; WHR, Waist to hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; PG, Plasma glucose; HOMA-IR, Homeostatic Model Assessment of Insulin
Resistance; M-value, Insulin sensitivity index; NEFA, non-esterified fatty acid; TCH, Total cholesterol; FAI, Free androgen index; SHBG, Sex hormone-binding globulin; LH, Luteinizing
hormone; FSH, Follicle stimulating hormone; TG, Triglycerides; HDL, High density lipoprotein; LDL, Low density lipoprotein; ALT, Alanine transaminase; HbA1c, hemoglobin A1c; TSH,
Thyroid stimulating hormone; DHEAS, Dehydroepiandrosterone.
from a cellular study using pancreatic-β cells (MIN6) suggested
fetuin-A to be a key intermediate protein in lipid-induced
cell death (28); however, we did not observe any changes
in fetuin-A levels following intralipid administration in our
study subjects.
The metabolic effects of FGF19 and FGF21 are broadly
similar and both regulate glucose homeostasis, improve insulin
sensitivity, and lower body weight (29). However, there are
subtle differences with regards to lipid metabolism. FGF19 has
a dual action on lipid metabolism; short term treatment with
FGF19 in diet induced obese mice resulted in a transient rise
in plasma TG by day 4 that returned to near baseline levels by
10 days. On the other hand, long term treatment with FGF19
lowers plasma TG and cholesterol in the same mouse model. The
effects of FGF19 are slightly different in leptin-deficient obese
ob/ob mice where both 1–2-week treatment with FGF19 resulted
in a consistent rise in TG and cholesterol levels (30). Despite
this rise in plasma lipids, FGF19 administration increased
insulin sensitivity evidenced by lowering plasma glucose and
insulin (30). Transgenic mice over-expressing the FGF19
protein are resistant to diet-induced diabetes. These animal
observations taken together indicates that pharmacological
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administration and transgenic expression of FGF19 increase
insulin sensitivity.
Interestingly, FGF19 levels were negatively correlated with
fasting plasma glucose (31) and shown to be decreased in
impaired fasting glucose, obesity, T2D, andNAFLD subjects. This
suggest a physiological role for endogenous FGF19 in glucose
metabolism and insulin sensitivity. We also observed lower
plasma FGF19 levels in insulin-resistant women with PCOS;
however, this was not statistically significant possibly due to our
smaller sample size. Available evidence in the literature, together
with our findings support the hypothesis that FGF19 is impaired
in subjects with IR.
In our study, insulin infusion increased FGF21 but did not
alter FGF19, FGF23, and fetuin-A in both PCOS and controls;
this is in agreement with previous reports that showed a rise in
serum and skeletal muscle FGF21 levels in overweight, obese,
and T2D subjects following an insulin infusion, (32) and no
change in FGF19 (33) and FGF23 (34) during hyperinsulinemia
in healthy volunteers. The increase in FGF21 by intralipid
infusion observed in our study may be a compensatory
mechanism to counter the dysregulated insulin signaling induced
by intralipid and the insulin clamp, and this raised FGF21
may contribute to the regulation of glucose uptake by muscle
and adipose tissue, thus regulating glucose homeostasis. In
agreement with this hypothesis data in rodents suggest that
overproduction of FGF21 prevents age-associated IR (35) and
improves metabolic abnormalities.
It is well-recognized that an intralipid infusion induces
IR through the Randle cycle by increasing plasma FFA and
triglycerides (16, 36). The elevated FFA further promotes release
of proinflammatory cytokines, alters carbohydrate metabolism,
induces IR in skeletal and cardiac muscle (37) and thus triggers
peripheral IR in healthy subjects. These effects could be amplified
in women with PCOS who have a higher degree of pre-existing
IR. In our study, lipid infusion stimulated steep rises in FGF21,
suppressed FGF19 and did not alter FGF23 and fetuin-A levels.
This is in agreement with a previous study that also reported
increased plasma FGF21 and no changes in fetuin-A following
an intralipid infusion in healthy volunteers (38). Similar findings
were also observed in dairy cows with increased NEFA, plasma,
and hepatic FGF21 production increased following intralipid
administration (39). Further in our study groups, the addition
of insulin along with lipid did not alter fetuin-A levels and did
not reverse lipid mediated suppression of FGF19. Interestingly,
a further rise in FGF21 was observed both in control and
PCOS women following administration of insulin along with
intralipids suggesting the synergistic action of intralipid and
insulin on FGF21. In controls, FGF23 levels were transiently
suppressed following 60min of insulin along with intralipids
and returned to near baseline values by 120min. Of relevance,
insulin-mediated suppression of FGF23 has been previously
reported in cell culture models (osteoblast-like cells UMR106
cells) and in rodents. In rodent’s, insulin deficiency increased
serum FGF23 which was reversed by insulin administration; and
a strong negative association was observed between FGF23 and
insulin in humans (40).
Regular physical activity promotes many health benefits and
reduces the risk of insulin resistance (19). Despite this, studies
have shown endurance training does not offer any protection
from FFA induced insulin resistance in trained individuals
(17). Disparity in the literature exists for effects of exercise on
endocrine FGFs and fetuin-A. In healthy lean men, 60-min short
term high intensity endurance exercise did not alter FGF19 levels,
although resistance exercise reduced FGF19 significantly (41).
In the same study, FGF21 increased with endurance but not
resistance exercise. (41) in healthy lean but not overweight, obese
and T2D subjects (32). Similarly, effects of exercise on FGF23 and
fetuin-A are also contradicting in mice, both acute and chronic
exercise increased serum FGF23 levels and was associated with
an increase in exercise performance (42). However, in human
volunteers, exercise did not alter circulating FGF23 (43). In
elderly over-weight men, 6 months of aerobic exercise increased
circulating fetuin-A. This raised fetuin-A was not related to
insulin sensitivity but was associated with VO2max (44). In a
recently published systematic review and meta-analysis study in
obese, T2D undergoing moderate to intense supervised exercise
reported a reduction in fetuin-A following exercise (45). In our
study cohort, 8 weeks of moderate intensity exercise did not have
any significant effects on FGF19, FGF21, FGF23, and fetuin-A
levels. Our results on FGF21 are in agreement with studies from
Kruse et al. (32) where the authors studied effects of 10-weeks
of aerobic training on FGF21 levels in serum samples from lean,
obese, and T2D subjects and found no significant changes in
FGF21 levels following exercise. Our results are in contrast to
that reported by Morville et al. (41) who reported whilst FGF19
was unchanged FGF21 increased with cycling exercise in trained
males; however, our study was conducted in over weight PCOS
and control women and the duration of exercise interval was
more chronic in comparison. Fetuin-A was found to be reduced
following exercise in adults and elderly (45), we did not observe
any changes in fetuin-A following exercise this may possibly
due to our smaller sample size. Despite not having any major
impact on endocrine FGFs or fetuin, exercise improved cardio-
respiratory fitness (Vo2 max) and insulin sensitivity measured
by changes in HOMA-IR, glucose disposal rate and M-value
(16). This is in agreement with previous studies which have
also reported no significant changes in body weight following
regular exercise (46). In spite of not having impact on weight
loss exercise reduces cardiometabolic risk, triglycerides, IR (47),
regularizing hormonal problems, improve insulin sensitivity,
improve ovulation (48) and has better outcome on fertility rates
in PCOS women.
This study has number of limitations. The study was
conducted in a small group of PCOS and healthy women given
the intense nature of study protocol requiring frequent blood
sampling, such interventional studies are challenging to perform
in a large group of subjects; hence our findings may not be
generalized. Similarly, our study did not take into account
ethnicity (all subjects were Caucasian), metabolic abnormalities,
phenotypic differences that usually exists in PCOS women. In
addition, BMI stratification would need to be undertaken in
future studies that would affect insulin resistance and hence may
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also influence expression of the proteins measured in this study.
Because of the small population selected it is possible that some
of the protein changes may have been missed due to the power of
the study.
CONCLUSION
This is the first study reporting the effects of intralipid and
insulin on endocrine FGFs and fetuin-A in women with PCOS.
Overall, these data suggest that FGF19 and FGF21 may have
a modulatory role in lipid and insulin metabolism as shown
by hyperinsulinemia and the lipid infusion. Lipid and insulin
synergistically increased FGF21 in healthy and insulin resistant
women with PCOS; hyperinsulinemia suppressed FGF19 in
controls (Table 2). However, lipid infusion mediated suppression
of FGF19 was not responsive to insulin in both controls and in
women with PCOS. Neither insulin nor intralipid- induced any
significant changes in the expression of FGF23 and fetuin-A.
The ISRCTN number for this study is ISRCTN42448814.
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